PCVX — Vaxcyte Inc

Vaxcyte Inc (PCVX) is a biotechnology company listed on NASDAQ. It is led by Grant E. Pickering M.B.A., based in 825 Industrial Road, San Carlos, CA, United States, 94070, with about 507 employees. Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Net income was -$520.1M. PCVX currently screens at market cap $6.84B.

Use this PCVX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PCVX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PCVX SEC filings page. Lician reads the product cache first so this HTML stays unique to Vaxcyte Inc even when a live quote feed is slow.